vs
STANDARD BIOTOOLS INC.（LAB）与PARKE BANCORP, INC.（PKBK）财务数据对比。点击上方公司名可切换其他公司
PARKE BANCORP, INC.的季度营收约是STANDARD BIOTOOLS INC.的1.2倍（$22.7M vs $19.6M），PARKE BANCORP, INC.净利率更高（48.8% vs -177.4%，领先226.2%），PARKE BANCORP, INC.同比增速更快（35.7% vs -11.5%），PARKE BANCORP, INC.自由现金流更多（$39.0M vs $-23.1M），过去两年PARKE BANCORP, INC.的营收复合增速更高（22.6% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Parke Bancorp, Inc.是总部位于美国的区域性银行控股公司，旗下运营Parke Bank，提供商业及零售银行全系列服务，包括存款产品、抵押贷款、小微企业融资、个人贷款等，主要服务新泽西州及费城大都会区域的客户。
LAB vs PKBK — 直观对比
营收规模更大
PKBK
是对方的1.2倍
$19.6M
营收增速更快
PKBK
高出47.2%
-11.5%
净利率更高
PKBK
高出226.2%
-177.4%
自由现金流更多
PKBK
多$62.0M
$-23.1M
两年增速更快
PKBK
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $22.7M |
| 净利润 | $-34.7M | $11.1M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | 64.2% |
| 净利率 | -177.4% | 48.8% |
| 营收同比 | -11.5% | 35.7% |
| 净利润同比 | -28.8% | 49.8% |
| 每股收益（稀释后） | $-0.09 | $0.93 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABPKBK
| Q4 25 | — | $22.7M | ||
| Q3 25 | $19.6M | $21.0M | ||
| Q2 25 | $21.8M | $18.7M | ||
| Q1 25 | $40.8M | $17.4M | ||
| Q4 24 | — | $16.8M | ||
| Q3 24 | $22.1M | $15.6M | ||
| Q2 24 | $22.5M | $15.5M | ||
| Q1 24 | $45.5M | $15.1M |
净利润LABPKBK
| Q4 25 | — | $11.1M | ||
| Q3 25 | $-34.7M | $10.6M | ||
| Q2 25 | $-33.5M | $8.3M | ||
| Q1 25 | $-26.0M | $7.8M | ||
| Q4 24 | — | $7.4M | ||
| Q3 24 | $-26.9M | $7.5M | ||
| Q2 24 | $-45.7M | $6.5M | ||
| Q1 24 | $-32.2M | $6.2M |
毛利率LABPKBK
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — |
营业利润率LABPKBK
| Q4 25 | — | 64.2% | ||
| Q3 25 | -168.5% | 64.2% | ||
| Q2 25 | -118.1% | 59.0% | ||
| Q1 25 | -80.8% | 59.1% | ||
| Q4 24 | — | 58.0% | ||
| Q3 24 | -120.9% | 60.2% | ||
| Q2 24 | -134.5% | 56.7% | ||
| Q1 24 | -132.2% | 55.4% |
净利率LABPKBK
| Q4 25 | — | 48.8% | ||
| Q3 25 | -177.4% | 50.6% | ||
| Q2 25 | -153.7% | 44.3% | ||
| Q1 25 | -63.8% | 44.6% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | -122.0% | 48.1% | ||
| Q2 24 | -203.3% | 41.6% | ||
| Q1 24 | -70.6% | 40.7% |
每股收益（稀释后）LABPKBK
| Q4 25 | — | $0.93 | ||
| Q3 25 | $-0.09 | $0.89 | ||
| Q2 25 | $-0.09 | $0.69 | ||
| Q1 25 | $-0.07 | $0.65 | ||
| Q4 24 | — | $0.61 | ||
| Q3 24 | $-0.07 | $0.62 | ||
| Q2 24 | $-0.12 | $0.53 | ||
| Q1 24 | $-0.27 | $0.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $324.5M |
| 总资产 | $539.6M | $2.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABPKBK
| Q4 25 | — | — | ||
| Q3 25 | $129.4M | — | ||
| Q2 25 | $158.6M | — | ||
| Q1 25 | $150.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $210.6M | — | ||
| Q2 24 | $269.8M | — | ||
| Q1 24 | $287.1M | — |
总债务LABPKBK
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABPKBK
| Q4 25 | — | $324.5M | ||
| Q3 25 | $399.7M | $314.8M | ||
| Q2 25 | $424.5M | $312.2M | ||
| Q1 25 | $454.6M | $305.9M | ||
| Q4 24 | — | $300.1M | ||
| Q3 24 | $489.3M | $296.5M | ||
| Q2 24 | $510.3M | $292.8M | ||
| Q1 24 | $577.3M | $288.4M |
总资产LABPKBK
| Q4 25 | — | $2.2B | ||
| Q3 25 | $539.6M | $2.2B | ||
| Q2 25 | $557.0M | $2.2B | ||
| Q1 25 | $579.6M | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | $681.5M | $2.1B | ||
| Q2 24 | $708.7M | $2.0B | ||
| Q1 24 | $777.7M | $2.0B |
负债/权益比LABPKBK
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $39.6M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $39.0M |
| 自由现金流率自由现金流/营收 | -118.1% | 171.3% |
| 资本支出强度资本支出/营收 | 4.5% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 3.57× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $63.5M |
8季度趋势，按日历期对齐
经营现金流LABPKBK
| Q4 25 | — | $39.6M | ||
| Q3 25 | $-22.2M | $11.4M | ||
| Q2 25 | $-20.7M | $6.8M | ||
| Q1 25 | $-30.3M | $7.0M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | $-27.9M | $9.4M | ||
| Q2 24 | $-39.0M | $8.9M | ||
| Q1 24 | $-62.5M | $8.3M |
自由现金流LABPKBK
| Q4 25 | — | $39.0M | ||
| Q3 25 | $-23.1M | $11.2M | ||
| Q2 25 | $-22.6M | $6.7M | ||
| Q1 25 | $-35.3M | $6.6M | ||
| Q4 24 | — | $35.0M | ||
| Q3 24 | $-30.1M | $9.4M | ||
| Q2 24 | $-41.0M | $8.9M | ||
| Q1 24 | $-63.3M | $8.3M |
自由现金流率LABPKBK
| Q4 25 | — | 171.3% | ||
| Q3 25 | -118.1% | 53.5% | ||
| Q2 25 | -103.6% | 35.8% | ||
| Q1 25 | -86.6% | 38.0% | ||
| Q4 24 | — | 209.1% | ||
| Q3 24 | -136.4% | 60.0% | ||
| Q2 24 | -182.2% | 57.1% | ||
| Q1 24 | -138.9% | 55.1% |
资本支出强度LABPKBK
| Q4 25 | — | 2.6% | ||
| Q3 25 | 4.5% | 0.5% | ||
| Q2 25 | 8.7% | 0.3% | ||
| Q1 25 | 12.4% | 2.2% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | 10.2% | 0.1% | ||
| Q2 24 | 8.6% | 0.2% | ||
| Q1 24 | 1.7% | 0.1% |
现金转化率LABPKBK
| Q4 25 | — | 3.57× | ||
| Q3 25 | — | 1.07× | ||
| Q2 25 | — | 0.82× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | 4.75× | ||
| Q3 24 | — | 1.25× | ||
| Q2 24 | — | 1.38× | ||
| Q1 24 | — | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
PKBK
暂无分部数据
